Literature DB >> 9018235

Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells.

M F Ledda1, S Adris, A I Bravo, C Kairiyama, L Bover, Y Chernajovsky, J Mordoh, O L Podhajcer.   

Abstract

Acquisition of invasive/metastatic potential is a key event in tumor progression. Cell surface glycoproteins and their respective matrix ligands have been implicated in this process. Recent evidence reveals that the secreted glycoprotein SPARC (secreted protein, acidic and rich in cysteine) is highly expressed in different malignant tissues. The present study reports that the suppression of SPARC expression by human melanoma cells using a SPARC antisense expression vector results in a significant decrease in the in vitro adhesive and invasive capacities of tumor cells, completely abolishing their in vivo tumorigenicity. This is the first evidence that SPARC plays a key role in human melanoma invasive-metastatic phenotype development.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9018235     DOI: 10.1038/nm0297-171

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  59 in total

Review 1.  SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury.

Authors:  A D Bradshaw; E H Sage
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  Characterization of SMOC-2, a modular extracellular calcium-binding protein.

Authors:  Christian Vannahme; Silke Gösling; Mats Paulsson; Patrik Maurer; Ursula Hartmann
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

3.  Integrin β4 regulates SPARC protein to promote invasion.

Authors:  Kristin D Gerson; Jeffrey R Shearstone; V S R Krishna Maddula; Bruce E Seligmann; Arthur M Mercurio
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

Review 4.  Recent advances in the treatment of malignant melanoma with gene therapy.

Authors:  E M Hersh; A T Stopeck
Journal:  Mol Med       Date:  1997-10       Impact factor: 6.354

5.  Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression.

Authors:  Rong Shao; Shideng Bao; Xuefang Bai; Carrie Blanchette; Ryan M Anderson; Tongyun Dang; Mikhail L Gishizky; Jeffrey R Marks; Xiao-Fan Wang
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

6.  Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity.

Authors:  Shawna L Bull Phelps; Juliet Carbon; Andrew Miller; Emely Castro-Rivera; Shanna Arnold; Rolf A Brekken; Jayanthi S Lea
Journal:  Am J Obstet Gynecol       Date:  2008-11-06       Impact factor: 8.661

7.  Differential Expression of SPARC in Intestinal-type Gastric Cancer Correlates with Tumor Progression and Nodal Spread.

Authors:  Konrad Franke; Stacy Carl-McGrath; Friedrich-Wilhelm Röhl; Uwe Lendeckel; Matthias Pa Ebert; Marc Tänzer; Matthias Pross; Christoph Röcken
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

8.  Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

Authors:  Alexandre Chlenski; Lisa J Guerrero; Radhika Peddinti; Jared A Spitz; Payton T Leonhardt; Qiwei Yang; Yufeng Tian; Helen R Salwen; Susan L Cohn
Journal:  Mol Cancer       Date:  2010-06-04       Impact factor: 27.401

9.  Downregulation of SPARC expression decreases gastric cancer cellular invasion and survival.

Authors:  Jie Yin; Guowei Chen; Yucun Liu; Si Liu; Pengyuan Wang; Yuanlian Wan; Xin Wang; Jing Zhu; Hongqiao Gao
Journal:  J Exp Clin Cancer Res       Date:  2010-06-02

10.  The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine.

Authors:  P Bhoopathi; C Chetty; M Gujrati; D H Dinh; J S Rao; S S Lakka
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.